PASW

Ping An Biomedical Co., Ltd. (PASW) 10Y Growth Potential Analysis (2026)

Invetso Score: 4.1/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Revenue Growth Drivers

Score: 4.8 (Moderate)

No disclosed 5-year revenue CAGR limits evidence of sustained compounding, while peers with reported multi-year growth can be assessed more clearly on repeatability.

Negative TTM ROIC suggests current capital deployment is not yet translating into scalable revenue expansion, unlike stronger peers that reinvest at positive returns.

Zero capex and R&D ratios imply limited visible reinvestment intensity, which can constrain future growth acceleration versus peers funding expansion more aggressively.

Negative interest coverage and negative EV metrics indicate a distressed operating base, reducing the likelihood of self-funded revenue compounding relative to healthier peers.

Market Tailwinds

Score:

No segment or concentration data is provided, so durable demand visibility cannot be established, unlike peers with clearer end-market exposure and recurring demand.

The absence of disclosed growth history weakens evidence that PASW benefits from persistent tailwinds that support multi-year revenue expansion.

Negative profitability metrics suggest any demand tailwind is not yet converting into durable economic scale, unlike peers with proven monetization.

Without segmentation evidence, it is unclear whether PASW can capture share in faster-growing niches as effectively as better-disclosed peers.

Scalability Expansion

Score:

Negative ROIC and negative interest coverage imply expansion is not yet self-funding, which structurally limits scaling versus peers with internal cash generation.

Zero capex and R&D intensity indicate little visible operating leverage or product reinvestment, reducing the path to scalable compounding.

Cash conversion cycle of 85.7 days suggests working-capital drag, which can slow expansion relative to peers with faster cash recycling.

The current financial profile points to constrained scalability, because growth would likely require external support rather than compounding from operating surplus.

Constraints Limitations

Score:

Negative ROIC is the clearest structural constraint, because it signals that incremental capital has not been compounding revenue or value versus peers.

Negative interest coverage indicates limited financial flexibility, which can cap expansion capacity and reduce resilience relative to better-capitalized peers.

The lack of reported historical growth metrics creates uncertainty, but the available profitability data still points to impaired scaling capacity.

Working-capital intensity and weak operating returns together suggest execution is not yet translating into durable long-term growth capacity.

Overall Score

Score:

PASW appears to have limited evidence of durable long-term compounding, with weak returns and constrained self-funded expansion offsetting any unproven growth potential.

Score Driver: Negative Roic

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Ping An Biomedical Co., Ltd.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →